Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
University of Geneva, Faculty of Medicine, Geneva, Switzerland.
Clin Microbiol Infect. 2023 Oct;29(10):1242-1248. doi: 10.1016/j.cmi.2022.08.010. Epub 2022 Aug 24.
Antibiotic therapy alone is unable to control recurrent urinary tract infection (UTI); uropathogens have become multiresistant, and alternative strategies are needed. Far from sterile, the urinary tract contains various low-biomass microbiota, some of whose members appear to protect against clinical UTI.
This narrative review summarizes (a) the current knowledge of male and female urobiomes in healthy and diseased states, as well as their interplay among sexual partners and (b) clinical trials to date assessing probiotic and other nonantibiotic measures to reduce UTI.
We used the PubMed interface to search Ovid Medline for articles describing urogenital flora, UTI, UTI dysbiosis, the effects of sexual intercourse on urogenital flora, and clinical trials of probiotics as UTI prophylaxis.
The healthy urobiome of women contains several Lactobacillus species, some of which may impede Escherichia coli growth in the urinary tract. Although Lactobacilli have been found in male urethral microbiota, their presence in male bladder microbiota is less certain. Distal male urethral and vaginal microbiomes of male and sexual female partners influence one another, but more research is needed on the direct interplay of their full urobiomes. Clinical trials assessing the therapeutic potential of Lactobacilli have been largely underpowered and highly varied in tested formulations and routes and frequencies of administration; as such, they have failed to show a clear benefit. Faecal microbiota transplantation for recurrent Clostridium difficile infection was shown, in a retrospective study of seven patients, to reduce recurrent UTI as a side effect.
The urobiome in men and women is complex, variable, and still understudied. Although there is hope that Lactobacilli and faecal microbial transplantation could be future nonantibiotic options for recurrent UTI, both require more pharmacologic and clinical research to identify optimal preparations and routes of administration.
仅用抗生素治疗无法控制复发性尿路感染(UTI);尿路病原体已产生多药耐药性,因此需要替代策略。尿路远非无菌,其中含有各种低生物量的微生物群,其中一些成员似乎可以预防临床 UTI。
本综述总结了(a)目前关于健康和患病状态下男性和女性尿生物群及其在性伴侣之间相互作用的知识,以及(b)迄今为止评估益生菌和其他非抗生素措施以减少 UTI 的临床试验。
我们使用 PubMed 界面在 Ovid Medline 上搜索描述泌尿生殖系菌群、UTI、UTI 失调、性交对泌尿生殖系菌群的影响以及益生菌作为 UTI 预防的临床试验的文章。
女性健康的尿生物群含有几种乳杆菌,其中一些可能会阻碍大肠杆菌在泌尿道的生长。尽管已经在男性尿道微生物群中发现了乳杆菌,但它们在男性膀胱微生物群中的存在不太确定。男性和有性生活的女性伴侣的远端男性尿道和阴道微生物群相互影响,但需要更多的研究来了解它们完整的尿生物群的直接相互作用。评估乳杆菌治疗潜力的临床试验大多缺乏效力,并且在测试的配方以及给药途径和频率方面差异很大;因此,它们未能显示出明显的益处。在对 7 名患者的回顾性研究中,粪菌移植治疗复发性艰难梭菌感染显示可减少复发性 UTI 作为副作用。
男性和女性的尿生物群复杂、多变,仍有待进一步研究。尽管乳杆菌和粪微生物移植可能是复发性 UTI 的未来非抗生素选择,但两者都需要更多的药理学和临床研究来确定最佳制剂和给药途径。